AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.66
+0.31 (+1.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.35
Open17.48
Bid17.62 x 1000
Ask17.68 x 800
Day's Range17.31 - 17.75
52 Week Range2.35 - 23.34
Volume3,985,892
Avg. Volume7,800,420
Market Cap5.703B
Beta (3Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • 2 Healthcare Stocks Ripe for a Takeover
    Motley Fool5 hours ago

    2 Healthcare Stocks Ripe for a Takeover

    Amarin and Aphria could both be bought out soon.

  • Amarin (AMRN) Gains As Market Dips: What You Should Know
    Zacks3 days ago

    Amarin (AMRN) Gains As Market Dips: What You Should Know

    Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day.

  • Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored
    Bloomberg3 days ago

    Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored

    Baker Bros., which was among the top 20 holders of the biotech stock at the end of September, sold its final 567,497 shares by the end of 2018, according to a regulatory filing this week. Baker Bros. didn’t immediately respond to a request for comment. To be sure, the New York-based hedge fund held just under half a million shares back in 2017 when Sage approached $100 per share after its lead asset saw success in another clinical trial.

  • GlobeNewswire3 days ago

    Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m. Eastern Time in New York City. Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science.

  • Amarin (AMRN) Stock Moves -0.49%: What You Should Know
    Zacks10 days ago

    Amarin (AMRN) Stock Moves -0.49%: What You Should Know

    Amarin (AMRN) closed at $16.15 in the latest trading session, marking a -0.49% move from the prior day.

  • Why Amarin Stock Jumped 29% in January After Soaring 239% Last Year
    Motley Fool13 days ago

    Why Amarin Stock Jumped 29% in January After Soaring 239% Last Year

    The Irish biotech company's stock started 2019 off with a bang thanks to two catalysts.

  • GlobeNewswire13 days ago

    Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Benzinga16 days ago

    Pharma Catches Another Case Of M&A Fever

    Is it 2018 all over again? While most investors will probably flinch at the suggestion, history is repeating itself somewhat in the pharmaceutical industry in the form of a frenzy of M&A announcements. ...

  • The Biggest Biotech Binary Event in 2019 Is Just Around the Corner
    Motley Fool19 days ago

    The Biggest Biotech Binary Event in 2019 Is Just Around the Corner

    Investors, mark your calendars.

  • ACCESSWIRE19 days ago

    Today's Research Reports on Trending Tickers: Amarin and Celgene

    NEW YORK, NY / ACCESSWIRE / January 29, 2019 / U.S. equities plunged on Monday following Caterpillar’s weaker-than-expected earnings report that dragged the tech sector lower. Additionally, fears over ...

  • Why Short-Sellers Raised Their Bets Against 2 Surging Biotech Stocks
    Motley Fool20 days ago

    Why Short-Sellers Raised Their Bets Against 2 Surging Biotech Stocks

    Find out why some aren't nearly as enthusiastic about the future for these two biotech stocks.

  • Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
    Zacks24 days ago

    Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool25 days ago

    3 Stocks That Are Absurdly Cheap Right Now

    Shares of Amarin, Baidu, and Tailored Brands are all incredible bargains at the moment. Here's why.

  • ACCESSWIRE25 days ago

    Today's Research Reports on Trending Tickers: Amarin and Immunomedics

    NEW YORK, NY / ACCESSWIRE / January 23, 2019 / U.S. markets declined on Tuesday, breaking a streak of four consecutive days in the green, on growing trade concerns. Stocks were pressured lower on reports ...

  • GlobeNewswire25 days ago

    New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session

    BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 23, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced.

  • 3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown
    Motley Fool26 days ago

    3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown

    No funding for the FDA means delays in drug reviews and approvals. And that could translate to bad news for these three biotechs.

  • Would Pfizer Shareholders Win With an Acquisition of Amarin?
    Motley Fool28 days ago

    Would Pfizer Shareholders Win With an Acquisition of Amarin?

    A Pfizer buyout of Amarin is still just a rumor. But rumors sometimes turn into reality.

  • Why Ligand Pharmaceuticals Tanked 25%
    Market Realistlast month

    Why Ligand Pharmaceuticals Tanked 25%

    Why Ligand Pharmaceuticals Tanked 25%Ligand PharmaceuticalsToday, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day. At the same time, other pharmaceutical companies Amarin

  • Why Amarin Is Soaring in First Half of January
    Market Realistlast month

    Why Amarin Is Soaring in First Half of January

    Why Amarin Is Soaring in First Half of JanuaryStock price hikeOn January 11, Amarin (AMRN) closed at $18.00, which is 1.91% lower than its previous closing price. However, on January 10, 2019, the company closed at $18.35, almost 22% higher than its

  • Why Amarin Stock Skyrocketed 239% in 2018 -- and Is Up 26% in 2019
    Motley Foollast month

    Why Amarin Stock Skyrocketed 239% in 2018 -- and Is Up 26% in 2019

    The Irish biotech company's stock has been on fire for two related reasons.

  • InvestorPlacelast month

    Sell Amarin Stock on the Recent Takeover Rumors Rally

    Shares of cardiovascular health sciences company Amarin (NASDAQ:AMRN) surged 22% on Thursday. That continues an amazing ride for the maker of Vascepa, an Omega-3 fatty acids treatment to fight very high triglycerides. Amarin stock has soared from $3 in September to as high as $23 following its decisive REDUCE-IT study results. These results showed that Amarin's formulation of Omega-3 oils performs superiorly to other generic options. After years of criticism, Amarin demonstrated that it isn't "just another fish oil pill" as the bears had always retorted. Since the trial results, Amarin stock has remained highly volatile. Yes, it's clear Amarin has a viable commercial product on their hands now, but how many doctors will start prescribing it? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks the Smart Money Is Piling Into Can Amarin make it as a standalone operation or does it need a larger commercial backer? All these questions came to a head on Thursday when rumors broke that Pfizer (NYSE:PFE) or perhaps AstraZeneca (NYSE:AZN) was going to acquire Amarin outright. Amarin stock soared. ### Pfizer Buying Amarin? Probably Not Biotech journalist and Twitter heavyweight Adam Feuerstein weighed in on the Pfizer rumors, tweeting: "Help me with the logic here: $AMRN CEO John Thero just spent 4 days in [San Francisco] meeting face to face with investors while ALSO negotiating a $PFE takeout? People, please…" It's not uncommon for biotech management teams to pull out of conferences when they are about to be acquired. Particularly if Amarin already knew that Pfizer or someone else would bid for the company, why bother with in-person investor relations? There'd be more important business to attend to. Also, it's worth noting that Pfizer's comments at that same biotech conference didn't indicate that a deal is coming soon. Pfizer's CEO Albert Bourla noted that the company greatly stepped up its share buyback in 2018. It did so, Bourla said, in order to be able to boost R&D spending without hitting earnings. Adding to that Bourla commented rather directly that: "In the years before we had an issue with growth, so we were looking to buy revenues now or soon because this is what was lacking. Right now we are not in this situation. Right now we are in a situation that our R&D is very productive and I feel that mostly R&D type of deals is what we need to enhance even further our pipeline, given that we have higher confidence in our capabilities to do it, given that now we have very good focus on R&D." Pfizer's CEO stated it clearly: they don't need to acquire more drugs to obtain growth. The R&D pipeline is stuffed. Pfizer is unlikely to want to drop $8 billion or more to acquire Amarin at this time. ### Amarin: Short-Term Struggles A lot of Amarin stock bulls expected shares to fly up toward $30 in the immediate wake of the shockingly good REDUCE-IT trial data. Analysts have pegged future peak annual sales estimates for Vascepa at $2 billion to $4 billion sometime in the 2020s. Given Amarin's healthy patent position on the drug, this has the makings of being a blockbuster therapeutic. There's still the hitch that the company needs to convince the FDA to expand its marketing label for the drug later this year. However, given the strong data, this shouldn't be too much of an issue. For now, however, Amarin is still experiencing relatively soft sales. Amarin released guidance suggested that it will sell just $350 million of Vascepa in 2019. That was well short of the market's expectations. So far, since the REDUCE-IT data came out, Amarin has seen a decent bump in its weekly prescriptions. They're up from 11,000 pre-data release to 15,000 now. That's solid progress. Still, it's clear that without much more marketing and/or a wider label approval from the FDA, it will take awhile for Amarin to gain serious sales traction. ### Amarin Stock Takeaway That said, Amarin finds itself in a decent position nonetheless. It had $249 million in cash as of the latest report, suggesting that it has time to ramp up its sales operations as a separate company. Amarin lost $98 million on $205 million in revenues last year, suggesting it isn't especially close to profitability. Analysts forecast a much smaller, but still negative, net income figure for this year as well. Regardless, with that cash position, Amarin isn't desperate to find a suitor and can wait for an attractive offer. For now, I see AMRN as a solid trading stock. When there are short-term rips, such as the 22% pop on the Pfizer rumors, it is a good time to take profits. When the stock dips, say on weaker than expected earnings or prescription fills data, you can buy back in at a better price. In the short-term, I consider it highly unlikely that Pfizer or someone else like AztraZeneca is about to purchase Amarin. The actions from both companies' management teams suggest that a deal is not imminent. As such, it makes sense to ring the register on AMRN stock following the recent move from $13.50 at the start of the year to $18 now. If you like the Amarin story, you will get another chance to buy back in at a cheaper price as there are no immediate catalysts to drive Amarin stock higher. At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post Sell Amarin Stock on the Recent Takeover Rumors Rally appeared first on InvestorPlace.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?

  • CNBClast month

    Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

    Two new deals to start the year and positive trial presentations at the J.P. Morgan Health Care conference have breathed new life into some of last year's biggest stock losers.

  • Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
    Zackslast month

    Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer

    Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.

  • Why Amarin Soared Over 22% Yesterday
    Market Realistlast month

    Why Amarin Soared Over 22% Yesterday

    Pharmaceutical company Amarin Corporation (AMRN) impressed investors by yielding an amazing 239.4% return in 2018, and its 2019 has started with a bang as well. Amarin stock has surged ~34.8% month-to-date as of its closing price on January 10. In 2018, the S&P 500 Index (SPY) and the NASDAQ Composite Index (QQQ) fell 6.2% and 3.9%, respectively.